



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Complete if Known**

Application Number	10/785,116
Filing Date	February 25, 2004
First Named Inventor	Iris PECKER et al
Art Unit	1652
Examiner Name	RICHARD G. HUTSON
Attorney Docket Number	27674

Sheet 1 of 33

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-2001/0006630	05-Jul-2001	Yacobi-Zeevi et al.	
	2	US-2002/0068061	06-Jun-2002	Peretz et al.	
	3	US-2002/0088019	04-Jul-2002	Yacoby-Zeevi	
	4	US-2002/0114801	22-Aug-2002	Pecker et al.	
	5	US-2002/0168749	14-Nov-2002	Pecker et al.	
	6	US-2002/0194625	19-Dec-2002	Zcharia et al.	
	7	US-2003/0031660	13-Feb-2003	Yacobi-Zeevi et al.	
	8	US-2003/0068806	10-Apr-2003	Ayal-HersHKovitz et al.	
	9	US-2003/0161823	28-Aug-2003	Ilan et al.	
	10	US-2003/0163836	28-Aug-2003	Garofalo et al.	
	11	US-2003/0170860	11-Sep-2003	Pecker et al.	
	12	US-2003/0181687	25-Sep-2003	Peretz et al.	
	13	US-2003/0190737	09-Oct-2003	Pecker et al.	
	14	US-2003/0217375	20-Nov-2003	Zcharia et al.	
	15	US-2004/0146497	29-Jul-2004	Ilan et al.	
	16	US-2,295,323	08-Sep-1942	Armstrong	
	17	US-4,117,841	03-Oct-1978	Perrotta et al.	
	18	US-4,937,747	26-Jun-1990	Koller	
	19	US-5,360,735	01-Nov-1994	Weinshank et al.	
	20	US-5,589,604	31-Dec-1996	Drohan et al.	
	21	US-5,700,671	23-Dec-1997	Prieto et al.	
	22	US-5,714,345	03-Feb-1998	Clark	
	23	US-5,716,817	10-Feb-1998	T?rnell	
	24	US-5,799,276	25-Aug-1998	Komissarchik et al.	
	25	US-5,799,311	25-Aug-1998	Agrawal et al.	
	26	US-5,830,759	03-Nov-1998	Chang et al.	
	27	US-5,859,929	12-Jan-1999	Zhou et al.	
	28	US-5,962,321	05-Oct-1999	Gough et al.	
Examiner Signature			Date Considered		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known Application Number: 10/785,116 Filing Date: February 25, 2004 First Named Inventor: Iris PECKER et al Art Unit: 1652 Examiner Name: RICHARD G. HUTSON		
Sheet	2	Of	33	Attorney Docket Number	27674	
U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ² (if known)				
	29	US-6,140,552	31-Oct-2000	Deboer et al.		
	30	US-6,190,875	20-Feb-2001	Ben-Artzi et al.		
	31	US-6,226,792	01-May-2001	Goiffon et al.		
	32	US-6,230,151	08-May-2001	Agrawal et al.		
	33	US-6,307,965	23-Oct-2001	Aggarwal et al.		
	34	US-6,314,420	06-Nov-2001	Lang et al.		
	35	US-6,426,209	30-Jul-2002	Ayal-HersHKovitz et al.		
	36	US-6,475,763	05-Nov-2002	Ayal-HersHKovitz et al.		
	37	US-6,562,950	13-May-2003	Peretz et al.		
	38	US-6,800,441	05-Oct-2004	Pecker et al.		
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	39	EP 0254067	27-Jan-1988	Cohen et al.		
	40	EP 0998569	10-May-2000	Pecker et al.		
	41	IL 133264	30-Apr-2001	Pecker et al.		
	42	AU 735116	28-Jun-2001	Pecker et al.		
	43	AU 768820	08-Jan-2004	Ben-Artzi et al.		
	44	PCT WO 00/03036	20-Jan-2000	Ben-Artzi et al.		
	45	PCT WO 00/25817	11-May-2000	Peretz et al.		
	46	PCT WO 00/52149	08-Sep-2000	Yacobi-Zeevi		
	47	PCT WO 00/52178	08-Sep-2000	Pecker et al.		
	48	PCT WO 01/00643	04-Jan-2001	Pecker et al.		
	49	PCT WO 02/19962	14-Mar-2002	Ilan et al.		
	50	PCT WO 02/32283	25-Apr-2002	Yacoby-Zeevi		
	51	PCT WO 03/006645	23-Jan-2003	Bohlen et al.		
	52	PCT WO 88/01280	25-Feb-1988	Nicolson et al.		
	53	PCT WO 91/02977	07-Mar-1991	Fuks et al.		
	54	PCT WO 91/19197	12-Dec-1991	Nicolson et al.		
	55	PCT WO 92/01003	23-Jan-1992	Nicolson et al.		
Examiner Signature			Date Considered			

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	10/785,116
Filing Date	February 25, 2004
First Named Inventor	Iris PECKER et al
Art Unit	1652
Examiner Name	RICHARD G. HUTSON

Sheet	3	Of	33	Attorney Docket Number	27674
-------	---	----	----	------------------------	-------

[illegible]Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Group Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	4	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	68	Abaza et al. "Effects of Amino Acid Substitutions Outside An Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration With Region 94-100 (Antigenic Site 3) of Myoglobin", Journal of Protein Chemistry, 11(5): 433-444, 1992.			
	69	Abrahamsohn et al. "Implantation and Decidualization in Rodents", J. Exp. Zool., 266(6): 603-628, 1993. Abstract.			
	70	Adams et al. "Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 3-174, 1995. GenBank Entry AA304653, 1997.			
	71	Agrawal "Antisense Oligonucleotides: Towards Clinical Trials", TIBTech, Trends in Biotechnology, 14: 376-387, 1996.			
	72	Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients With Cystic Fibrosis", J. Clin. Microbiol., 26(12): 2505-2509, 1988. Abstract.			
	73	Allison et al. "Polysaccharide Production in Pseudomonas Cepacia", J. Basic. Microbiol., 34(1): 3-10, 1994. Abstract.			
	74	Anatolii "Hyaluronic Capsule as One of the Factors of Hemolytic Streptococcus Pathogenicity", Chem. Abstracts 86(17): 339, 1977. Abstr.118714 in Zh. Mikrobiol. Epidemiol. Immunobiol., 2: 22-27, 1977.			
	75	Aoki et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides Into the Myocardium Using HVJ-Liposome Method", Biochemical and Biophysical Research Communications, 231: 540-545, 1997.			
	76	Aplin "Adhesion Molecules in Implantation", Reviews of Reproduction, 2(2): 84-93, 1997.			
	77	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children With Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 156(4 Pt.1): 1197-1204, 1997. Abstract.			
	78	Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", J. Vet. Med. Sci., 59(8): 727-728, 1997. Abstract.			
	79	Aspenberg et al. "Dose-Dependent Stimulation of Bone Induction by Basic Fibroblast Growth Factor in Rats", Acta Orthop. Scand., 62(5): 481-484, 1991. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	5	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	80	Aspenberg et al. "Fibroblast Growth Factor Stimulates Bone Formation. Bone Induction Studied in Rats", Acta Orthop. Scand., 60(4): 473-476, 1989. Abstract.			
	81	Aviezer et al. "Differential Structural Requirements of Heparin and Heparan Sulfate Proteoglycans That Promote Binding of Basic Fibroblast Growth Factor to Its Receptor", J. Biol. Chem., 269(1): 114-121, 1994.			
	82	Azghani et al. "A Beta-Linked Mannan Inhibits Adherence of Pseudomonas Aeruginosa to Human Lung Epithelial Cells", Glycobiology, 5(1): 39-44, 1995. Abstract.			
	83	Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomonas Aeruginosa Requires Facilitated Transport of D-Glucose by Macrophages", J. Immunol., 154(7): 3420-3428, 1995. Abstract.			
	84	Bartlett et al. "Comparative Analysis of the Ability of Leucocytes, Endothelial Cells, and Platelets to Degrade the Subendothelial Basement Membrane: Evidence for Cytokine Dependence and Detection of A Novel Sulfatase", Immunology and Cell Biol., 73: 113-124, 1995.			
	85	Basu et al. "Analysis of Glycosphingolipids by Fluorophore-Assisted Carbohydrate Electrophoresis Using Ceramide Glycanase From Mercenaria Mercenaria", Analytical Biochemistry, 222: 270-274, 1994.			
	86	Bean et al. "Fertilization In Vitro Increases Non-Disjunction During Early Cleavage Divisions in A Mouse Model System", Human Reproduction, 17(9): 2362-2367, 2002. Abstract.			
	87	Benathan et al. "Living Epidermal and Dermal Substitutes for Treatment of Severely Burned Patients", Rev. Med. Suisse Romande, 118(2): 149-153, 1998. Abstract-Art. in French.			
	88	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", J. Histochem. Cytochem. 43: 881-886, 1995.			
	89	Bendig et al. "Humanization of Rodent Monoclonal Antibodies by CDR Grafting", Methods in Enzymology, 8: 83-93, 1995.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	6	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	90	Benezra et al. "Reversal of Fibroblast Growth Factor-Mediated Autocrine Cell Transformation by Aromatic Anionic Compounds", Cancer Research, 52: 5656-5662, 1992.			
	91	Benezra et al. "Thrombin Enhances the Degradation of Heparan Sulfate in the Extracellular Matrix by Tumor Cell Heparanase", Exptl. Cell. Res., 201: 208-215, 1992.			
	92	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling Is Defined by Pericyte Coverage of the Preformed Endothelial Network and Is Regulated by PDGF-B and VEGF", Development, 125: 1591-1598, 1998.			
	93	Bennett et al. "Effect of Uridine 5'-Triphosphate Plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 153(6 Pt.1): 1796-1801, 1996. Abstract.			
	94	Berkow "The Merck Manual", Merck Research Laboratories, P.201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601, 1997.			
	95	Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Tissue", Eur. J. Clin. Microbiol., 6(5): 591-593, 1987. Abstract.			
	96	Bhaskar et al. "Dysregulation of Proteoglycan Production by Intrahepatic Biliary Epithelial Cells Bearing Defective (Delta-f508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatology, 27(1): 7-14, 1998. Abstract.			
	97	Bischof et al. "The Regulation of Endometrial and Trophoblastic Metalloproteinases During Blastocyst Implantation", Contracept Fertil Sex, 22(1): 48-51, 1994. Abstract. Article in French.			
	98	Blancaert et al. "CMDBS, Functional Analogs of Sulfate Heparanes, Used as Osseous Cicatrizing Agents", Ann. Endocrinol., 55(2): 121-123, 1994. Abstract.			
	99	Blancaert et al. "Heparan-Like Molecules Induce the Repair of Skull Defects", Bone, 17(6): 499-506, 1995. Abstract.			
	100	Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract.			
	101	Boat et al. "Epithelial Cell Dysfunction in Cystic Fibrosis: Implications for Airways Disease", Acta Paediatr. Scand.			
Examiner Signature					Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/785,116	
				Filing Date		February 25, 2004	
				First Named Inventor		Iris PECKER et al	
				Art Unit		1652	
				Examiner Name		RICHARD G. HUTSON	
Sheet	7	Of	33	Attorney Docket Number		27674	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²	
	102	Bork "Go Hunting in Sequence Databases But Watch Out for the Traps", Trends in Genetics, 12(10): 425-427, 1996.					
	103	Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome Research, 10 : 398-400, 2000.					
	104	Bost et al. "Antibodies Against A Peptide Sequence Within the HIV Envelope Protein Crossreacts With Human Interleukin-2", Immunol. Invest., 17: 577-586, 1988.					
	105	Boucher et al. "Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis: Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in A Mouse Model of Respiratory Infection", Infect. Immun., 65(9): 3838-3846, 1997. Abstract.					
	106	Boucher et al. "Two Distinct Loci Affecting Conversion to Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", J. Bacteriol., 178(2): 511-523, 1996. Abstract.					
	107	Bowie et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science, 247: 1306-1310, 1990.					
	108	Brenner "Errors in Genome Annotation", Trends in Genetics, 15(4): 132-133, 1999.					
	109	Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires Effective Recipient Preparation", Biology of Reproduction 69: 412-420, 2003. Abstract.					
	110	Burch et al. "Oligodeoxynucleotides Antisense to the Interleukin 1 Receptor mRNA Block the Effects of Interleukin 1 in Cultured Murine and Human Fibroblasts and in Mice", Journal of Clinical Investigation, 88: 1190, 1991. Abstract.					
	111	Burrows et al. "Trophoblast Migration During Human Placental Implantation", Hum. Reprod. Update, 2(4): 307-321, 1996.					
	112	Cai et al. "Comparison of Sputum Processing Techniques in Cystic Fibrosis", Pediatr. Pulmonol., 22(6): 402-407, 1996. Abstract.					
	113	Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Differential Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotides: An In Vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA, 88: 2351-2355, 1991.					
Examiner Signature					Date Considered		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/785,116	
				Filing Date		February 25, 2004	
				First Named Inventor		Iris PECKER et al	
				Art Unit		1652	
				Examiner Name		RICHARD G. HUTSON	
Sheet	8	Of	33	Attorney Docket Number		27674	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
	114	Campbell et al. "Comparison of the Whey Acidic Protein Genes of the Rat and Mouse", Nucleic Acids Res., 12(22): 8685-8697, 1984.					
	115	Carlone et al. "Embryonic Modulation of Basic Fibroblast Growth Factor in the Rat Uterus", Biology of Reproduction, 49(4): 653-665, 1993.					
	116	Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824, 1998.					
	117	Carson et al. Mucin and Proteoglycan Functions in Embryo Implantation", BioEssays, 20(7): 577-583, 1998. Abstract, P.580, Col.2, § 2, P.582, Col 1, Fig.1.					
	118	Chang et al. "Differential Ability of Heparan Sulfate Proteoglycans to Assemble the Fibroblast Growth Factor Receptor Complex In Situ", FASEB Journal, 14: 137-144, 2000.					
	119	Cheng et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelia Cells From Patients With Cystic Fibrosis", Journal of Clinical Investigation, 84(1): 68-72, 1989. Abstract.					
	120	Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.					
	121	Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged Proteins in Mammalian Cells", BioTechniques, 20: 136-141, 1996.					
	122	Cohen "Oligonucleotide Therapeutics", Trends in Biotechnology 10: 87-91, 1992. Abstract.					
	123	Coligan et al. "Current Protocols in Immunology", Immunology - Laboratory Manuals, 1991.					
	124	Colman "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions", Research in Immunology, 145(1): 33-36. 1994. Suppl. IDS in 25783;					
	125	Coombe et al. "Analysis of the Inhibition of Tumor Metastasis by Sulphated Polysaccharides", Int. J. Cancer, 39: 82-88, 1987. Abstract.					
	126	Crystal "Gene Therapy Strategies for Pulmonary Disease", American Journal of Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992.					
Examiner Signature						Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	9	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	127	Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and RhDNase", Pediatric Pulmonology, 22: 161-166, 1996.			
	128	Davies et al. "Regulation of the Alginate Biosynthesis Gene AlgC in Pseudomonas Aeruginosa During Biofilm Development in Continuous Culture", Appl. Environ. Microbiol., 61(3): 860-867, 1995. Abstract.			
	129	De Vouge et al. "Immunoselection of GRP94/Endoplasmin From A KNRK Cell-Specific ?gt11 Library Using Antibodies Directed Against A Putative Heparanase Amino-Terminal Peptide", Int. J. Cancer, 56: 286-294, 1994.			
	130	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.			
	131	Dibrino "RT-PCR Method & Applications", Clontech Laboratories, 1st Ed., 1: 11, 15, 23, 41, 26, 1991.			
	132	Doerks et al. "Protein Annotation: Detective Work for Function Prediction", Trends in Genetics, 14(6): 248-250, 1998.			
	133	Doetschman "Interpretation of Phenotype in Genetically Engineered Mice", Laboratory Animal Science, 49(2): 137-143, 1999.			
	134	Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide From A Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology, 162(2): 504-509, 1985. Abstract.			
	135	Ducy et al. "The Osteoblast: A Sophisticated Fibroblast Under Central Surveillance", Science, 289: 1501-1504, 2000.			
	136	Duff "Transgenic Mice Overexpressing Presenilin cDNAs: Phenotype and Utility in the Modeling of Alzheimer's Disease", Central Nervous System Diseases, P.123-128, 2000. Abstract.			
	137	Duffy et al. "Maximizing Flap Survival in A Prefabrication Model Using Exogenous and Endogenous bFGF: A New Approach", Microsurgery, 17(4): 176-179, 1996. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	10	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	138	Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.			
	139	Edwards et al. "Some Properties and Applications of Monoclonal Antibodies", Biochem. Journal, 200: 1-10, 1981.			
	140	Ehle et al. "Immunoaffinity Chromatography of Enzymes", Bioseparation, 1(2): 97-110, 1990.			
	141	Ejima et al. "Induction of Apoptosis in Placentas of Pregnant Mice Exposed to Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System", Biology of Reproduction, 62: 178-185, 2000. Abstract.			
	142	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB Journal, 15: 1661-1663, 2001.			
	143	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB Journal, Published Online, 10 P. 2001.			
	144	Ennis et al. "Rapid Cloning of HLA-A,B cDNA by Using the Polymerase Chain Reaction: Frequency and Nature of Errors Produced in Amplification", PNAS USA, 87: 2833-2837, 1990.			
	145	Esko et al. "Tumor Formation Dependent on Proeoglycans Biosynthesis", Science, 241(4869): 1092-1096, 1988. Abstract.			
	146	Evans et al. "Human Chromosome 11 187a8 Cosmid, Complete Sequence", Database EMBL, Accession No. U73640, XP002198427, 1996. Abstract.			
	147	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", J. Clin. Invest., 97(1): 162-171, 1996.			
	148	Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", The Journal of Biological Chemistry, 274(42): 29587-29590, 1999.			
	149	Farndale et al. "A Direct Spectrophotometric Microassay for Sulfated Glycosaminoglycans in Cartilage Cultures", Connective Tissue Research, 9: 247-248, 1982.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	11	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	150	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia", Nature Medicine, 6(5): 568-572, 2000.			
	151	Finkel "Potential Target Found for Antimetastasis Drugs", Science, 285: 33-34, 1999.			
	152	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense Oligodeoxynucleotides", Molecular and Cellular Biochemistry, 172: 213-225, 1997.			
	153	Frederiksen et al. "Antibiotic Treatment of Initial Colonization with Pseudomonas Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary Function in Cystic Fibrosis", Pediatr. Pulmonol. 23(5): 330-335, 1997. Abstract.			
	154	Frederiksen et al. "Changing Epidemiology of Pseudomonas Aeruginosa Infection in Danish Cystic Fibrosis Patients (1974-1995)", Pediatr. Pulmonol., 28(3): 159-166, 1999. Abstract.			
	155	Freeman et al. "A Rapid Quantitative Assay for the Detection of Mammalian Heparanase Activity", Biochemical Journal, 325: 229-237, 1997.			
	156	Friedman et al. "Regulated Expression of Homeobox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests A Role in Hormone Action and Epithelial-Stromal Interactions", Developmental Biology, 177: 347-355, 1996.			
	157	Gabriel et al. "In Vitro Adherence of Pseudomonas Aeruginosa to Four Intraocular Lenses", J. Cataract Refract Surg., 24: 124-129, 1998.			
	158	Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite Protein and Thrombospondin Is Mediated by Its Glycosaminoglycan-Binding Region and Not by CSVTCG", J. Biol. Chem., 272(31): 19205-19213, 1997. Abstract.			
	159	Garner "Epidermal Regulation of Dermal Fibroblast Activity", Plast. Reconstr. Surg., 102(1):135-139, 1998. Abstract.			
	160	Gewirtz et al. "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise", Proc. Natl. Acad. Sci. USA, 93: 3161-3163, 1996.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	12	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	161	Gewirtz et al. "Nucleic Acid Therapeutics: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.			
	162	Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill Biofilms of Mucoid Pseudomonas Aeruginosa", Can. J. Microbiol., 43(11): 999-1004, 1997. Abstract.			
	163	Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions as An Extracellular Matrix-Degrading Enzyme or as A T-Cell Adhesion Molecule, Depending on the Local PH", Journal of Experimental Medicine, 181: 1929-1934, 1995.			
	164	Giuffre et al. "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-Selectin and Heparan Sulfate Proteoglycans", J. Cell Biol., 136(4): 945-956, 1997. Abstract.			
	165	Godder et al. "Heparanase Activity in Cultured Endothelial Cells", Journal of Cellular Physiology, 148: 274-280, 1991.			
	166	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by Chondrocytes in Culture", Live Tissue Research, 24: 265-275, 1990.			
	167	Goldshmidt et al. "Cell Surface Expression and Secretion of Heparanase Markedly Promote Tumor Angiogenesis and Metastasis", Proc. Natl. Acad. Sci. USA, 99(15): 10031-10036, 2002.			
	168	Gordon-Cardo et al. "Expression of Basic Fibroblast Growth Factor in Normal Human Tissues"; Laboratory Investigation, 63: 832-840, 1990. Abstract.			
	169	Gorodetsky et al. "Isolation and Characterization of the Bos Taurus β -Casein Gene", Gene, 66: 87-96, 1988. Abstract.			
	170	Gottschalk et al. "Somatic Gene Therapy. Present Situation and Future Perspective", Arzneimittelforschung, 48(11): 1111-1120, 1998. Abstract.			
	171	Green et al. "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease", Journal of American Cell Surgery, 191(1): 93-105, 2000.			
	172	Guriec et al. "CD44 Isoforms With Exon V6 and Metastasis of Primary N0M0 Breast Carcinomas", Breast Cancer Res. Treat., 44(3):261-268, 1997. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/785,116	
				Filing Date		February 25, 2004	
				First Named Inventor		Iris PECKER et al	
				Art Unit		1652	
				Examiner Name		RICHARD G. HUTSON	
Sheet	13	Of	33	Attorney Docket Number		27674	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²	
	173	Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by Theileria Sergenti Merozoites", Int. J. Parasitol., 27(5): 535-539, 1997. Abstract.					
	174	Haimov-Kochman et al. "Localization of Hepranase in Normal and Pathological Human Placenta", Molecular Human Reproduction, 8(6): 566-573, 2002.					
	175	Hammer et al. "Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human ?2m: An Animal Model of HLA-B27-Associated Human Disorders", Cell, 63: 1099-1112, 1990.					
	176	Harlow et al. "Antibodies - A Laboratory Manual", Cold Spring Harbor Press, P. 471-510, 1988.					
	177	Harvey et al. "Expression of Exogenous Protein in the Egg White of Transgenic Chickens", Nature Biotechnology, 19: 396-399, 2002.					
	178	Hatano et al. "Biologic Activities of Antibodies to the Neutral-Polysaccharide Component of the Pseudomonas Aeruginosa Lipopolysaccharide Are Blocked by O Side Chains and Mucoic Acid Exopolysaccharide (Alginate)", Infect. Immun., 63(1): 21-26.					
	179	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminoglycosides Through the Extracellular Polysaccharide of Mucoic Pseudomonas Aeruginosa", Antimicrob. Agents. Chemother., 42(4): 974-977, 1998. Abstract.					
	180	Hayward et al. "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic Shock", American Journal of Physiology, 275: H23-H30, 1998.					
	181	Herrera et al. "Mediation of Trypanosoma Cruzi Invasion by Heparan Sulfate Receptors on Host Cells and Penetrin Counter-Receptors on the Trypanosomes", Molecular & Biochemical Parasitology, 65(1): 73-83, 1994. Abstract.					
	182	Hida et al. "Antisense E1AF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", Am. J. Pathol., 50(6): 2125-2132, 1997. Abstract.					
	183	Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mouse Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.					
Examiner Signature					Date Considered		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	14	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	184	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996.			
	185	Hillier et al. "The WashU-Merck EST Project", Database EMBL Accession No. N45367, XP 002198420, 1996. Abstract.			
	186	Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996.			
	187	Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996.			
	188	Hoffman et al. "Human Bone Morphogenic Protein 2 Contains A Heparin-Binding Site Which Modifies Its Biological Activity", Eur. J. Biochem., 237(1): 295-302, 1996. Abstract.			
	189	Hoogewerf et al. "CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 Are Heparin/Heparan Sulfate-Degrading Enzymes", Journal of Biological Chemistry, 270(7): 3268-3277, 1995.P.3269.			
	190	Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First Intron in Expression of the $\alpha 1$ (I) Collagen Gene.", Mol Cell Biol., 18(6): 3368-3375, 1998. Abstract.			
	191	Hsueh et al. "Invasive Streptococci Pneumoniae Infection Associated With Rapidly Fatal Outcome in Taiwan", J. Formos Med. Assoc., 95(5): 364-371, 1996. Abstract.			
	192	Hudson "Recombinant Antibody Fragment", Curr. Opin. Biotech., 4:395-402, 1998. Abstract.			
	193	Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract]			
	194	Inui et al. "Local Application of Basic Fibroblast Growth Factor Minipellet Induces the Healing of Segmental Bony Defects in Rabbits", Calcified Tissue International, 63(6): 490-495, 1998. Abstract.			
	195	Irimura et al. "Chemically Modified Heparins as Inhibitors of Heparan Sulfate Specific Endo- β -Glucuronidase (Heparanase) of Metastatic Melanoma Cells", Biochemistry, 25: 5322-5328, 1986. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	15	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	196	Jackson "The Use of Polyacrylamide-Gel Electrophoresis for the High-Resolution of Separation of Reducing Saccharides Labelled With the Fluorophore 8-Aminonaphtalene-1, 3, 6-Trisulphonic Acid", Biochem J., 270: 705-713, 1990.			
	197	Jayaraman et al. "Rational Selection and Quantitative Evaluation of Antisense Oligonucleotides", Biochimica et Biophysica Acta, 1520: 105-114, 2001.			
	198	Jin et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", International Journal of Cancer, 45: 1088-1095, 1990.			
	199	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA", Proceedings American Association for Cancer Research Annual Meeting, 1992, 33: 57, 1992. Abstract.			
	200	Johansen et al. "Vaccination Promotes TH1-Like Inflammation and Survival in Chronic Pseudomonas Aeruginosa Pneumonia: A New Prophylactic Principle", Behring Institut Mitteilungen, 98: 269-273, 1997. Abstract.			
	201	Jorba et al. "Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars", Rev. Esp. Fisiol., 36(2): 155-161, 1980. Abstract.			
	202	Jusa et al. "Effect of Heparinon on Infection of Cells by Porcine Reproductive and Respiratory Syndrome Virus", American Journal of Vet. Res., 58(5): 488-491, 1997. Abstract.			
	203	Kang et al. "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine beta-Casein Gene", Mol. Cells, 8(3): 259-265, 1998. Abstract.			
	204	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain From An Inhibitor to A Potent Activator of FGF-2", Nature Medicine, 4(6): 691-697, 1998.			
	205	Kawaja et al. "Employment of Fibroblasts for Gene Transfer: Applications for Grafting Into the Central Nervous System", Genetic Engineering. NY, 13: 205-220, 1991. Abstract.			
	206	Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo-Micromanipulator for In Vitro Fertilization Using Frozen-Thawed Mouse Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell Stage", Biology of Reproduction, 66: 3810385, 2002. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	16	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	207	Kiberstis et al. "Bone Health in the Balance", Science, 289: 1497, 2000.			
	208	Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta", Placenta, 24: 424-430, 2003.			
	209	Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During Gestation", Reproduction, 121: 573-580, 2001. Suppl. IDS in 23665;			
	210	Köhler et al. "Continuous Cultures of Fused Cells Secreting Antibody of Preddefined Specificity", Nature, 256: 495-497, 1975.			
	211	Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997.			
	212	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part II. Use of Therapies", Pediatr. Pulmonol., 28(4): 248-54, 1999. Abstract.			
	213	Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.			
	214	Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", Molecular Biology/Biochemistry, Proceedings of the American Association for Cancer Research, 37: 495, 1996.			
	215	Kosir et al. "Human Prostate Carcinoma Cells Produce Extracellular Heparanase", Journal of Surgical Research, 67: 98-105, 1997.			
	216	Krivit et al. "Microglia: The Effector Cell for Reconstitution of the Central Nervous System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal Storage Diseases", Cell Transplant, 4(4): 385-392, 1995. Abstract.			
	217	Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset", Blood, 91(3): 852-862, 1998.			
	218	Krusat et al. "Heparin-Dependent Attachment of Respiratory Syncytial Virus (RSV) to Host Cells", Arch. Virol., 142(6): 1247-1254, 1997. Abstract.			
	219	Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.			
	220	Kuyvenhoven et al. "Assessment of Serum Matrix Metalloproteinases MMP-2 and MMP-9 After Human Liver Transplantation: Increased Serum MMP-9 Level in Acute Rejection", Transplantation, 77(11): 1646-1652, 2004. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	17	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	221	Lai et al. "DNA Vaccines", Critical Reviews in Immunology, 18: 449-484, 1998.			
	222	Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.			
	223	Lampard et al. "Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene Regulatory Sequences", Biochem. Cell Biol., 80(6): 777-788, 2002. Abstract.			
	224	Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer, 47(1): 92-98, 1991.			
	225	Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.			
	226	Lederman et al. "A Single Amino Acid Substitution in A Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4", Molecular Immunology, 28: 1171-1181, 1991.			
	227	Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of Borrelia burgdorferi to Cultured Endothelial and Brain Cells", Infect. Immun., 66(3): 994-999, 1998. Abstract.			
	228	Lessey et al. "Paracrine Signaling in the Endometrium: Integrins and the Establishment of Uterine Receptivity", J. Reprod. Immunol., 39(1-2): 105-116, 1998. Abstract.			
	229	Li et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer, 45: 1088-1095, 1990.			
	230	Li et al. "In Vivo Fragmentation of Heparan Sulfate by Heparanase Overexpression Renders Mice Resistant to Amyloid Protein A Amyloidosis", PNAS, 102(18): 6473-6477, 2005.			
	231	Li et al. "β-Endorphin Omission Analogs: Dissociation of Immunoreactivity From Other Biological Activities", PNAS, 77: 3211-3214, 1980.			
	232	Lider et al. "Inhibition of T Lymphocyte Heparanase by Heparin Prevents T Cell Migration and T Cell-Mediated Immunity", European Journal of Immunology, 20(3): 493-499, 1990. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	18	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	233	Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.			
	234	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes From Cryopreserved Primordial Mouse Follicles After Sequential In Vivo Transplantation and In Vitro Maturation", Biology of Reproduction, 64: 171-178, 2001. Abstract.			
	235	Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", Am. J. Vet. Res., 57(4): 554-559, 1996.			
	236	Luft " Making Sense Out of Antisense Oligodeoxynucleotide Delivery: Getting There Is Half the Fun". J. Mol. Med, P.75-76. 1998.			
	237	Macone et al. "Mucoid Escherichia Coli in Cystic Fibrosis", The New England Journal of Medicine, 304(24): 1445-1449, 1981. Abstract.			
	238	Maillard et al. "Pre-Treatment With Elastase Improves the Efficiency of Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media", Gene Therapy, 5: 1023-1030, 1998.			
	239	Marchetti et al. "Neurotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", Cancer Research, 56: 2856-2863, 1996. Also in: Advances in Enzyme Regulation, 37: 111-134, 1997.			
	240	Marra et al. ""The WashU-HHMI Mouse EST Project", Database EMBL, Accession No. A1122034, XP 002198426, 1998. Abstract.			
	241	Marra et al. "The WashU-HHMI Mouse Est Project", Database EMBL, Accession No. AA047943, XP002198424, 1996.			
	242	Marty et al. "Influence of Nutrient Media on the Chemical Composition of the Expolysaccharide From Mucoid and Non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, 77(1-3): 35-44, 1992. Abstract.			
	243	Massague "The TGF-BETA Family of Growth and Differentiation Factors", Cell, 49: 437-438, 1987.			
	244	Mateo et al. "Humanization of A Mouse Monoclonal Antibody That Blocks the Epidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	19	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	245	Matoba et al. "Evaluation of Omental Implantation for Perforated Gastric Ulcer Therapy: Findings in A Rat Model", J. Gastroenterol., 31(6): 777-784, 1996. Abstract.			
	246	Matzner et al. "Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by A Readily Released Heparanase From Human Neutrophils", Journal of Clinical Investigation, 76(4): 1306-1313, 1985.			
	247	McKenzie et al. "Biochemical Characterization of the Active Heterodimer Form of Human Heparanase (Hpa I) Protein Expressed in Insect Cells", Biochemical Journal, 373: 423-435, 2003.			
	248	Meluleni et al. "Mucoid Pseudomonas Aeruginosa Growing in A Biofilm In Vitro Are Killed by Opsonic Antibodies to the Mucoid Exopolysaccharide Capsule But Not by Antibodies Produced During Chronic Lung Infection in Cystic Fibrosis Patients", J. Immun., 155(4): 2029-2038, 1995. Abstract.			
	249	Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive BioMedicine Online 2002, 4(2): 170-175, 2002. Abstract.			
	250	Mengistu et al. "Continuous Culture Studies on the Synthesis of Capsular Polysaccharide by Klebsiella Pneumoniae K1", J. Appl. Bacteriol., 76(5): 424-430, 1994. Abstract.			
	251	Miao et al. "Cloning, Expression and Purification of Mouse Heparanase", Protein Expression and Purification, 26: 425-431, 2002.			
	252	Miao et al. "Modulation of Fibroblast Growth Factor-2 Receptor Binding Dimerization, Signaling, and Angiogenic Activity by A Synthetic Heparin-Mimicking Polyaromatic Compound", J. Clin. Invest., 99(7): 1565-1575, 1997.			
	253	Miller et al. "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-1732, 1993. Abstract.			
	254	Mirault et al. "Transgenic Glutathione Peroxidase Mouse Models for Neuroprotection Studies", Ann. NY Acad. Sci., 738: 104-115, 1994. Abstract.			
	255	Miyake et al. "Highly Specific and Sensitive Detection of Malignancy in Urine Samples From Patients With Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", Int. J. Cancer, 79(6): 560-564, 1998. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	20	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	256	Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulfate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", <i>Pediatr. Res.</i> , 38(1): 42-48, 1995. Abstract.			
	257	Mollinedo et al. "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochemical Journal</i> , 327: 917-923, 1997.			
	258	Morrison et al. "Sequences in Antibody Molecules Important for Receptor-Mediated Transport Into the Chicken Egg Yolk", <i>Mol. Immunol.</i> , 38(8): 619-625, 2002.			
	259	Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe in Th2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice", <i>APMIS</i> , 105(11): 838-842, 1997. Abstract.			
	260	Moses et al. "Relative Contributions of Hyaluronic Capsule and M Protein to Virulence in A Mucoid Strain of the Group A Streptococcus", <i>Infect. Immun.</i> , 65(1): 64-71, 1997.			
	261	Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone In Vivo", <i>Blood</i> , 88(4): 1314-1320, 1996. Abstract.			
	262	Mullins et al. "Expression of the DBA/2J Ren-2 Gene in the Adrenal Gland of Transgenic Mice", <i>The EMBO Journal</i> , 8(13): 4065-4072, 1989.			
	263	Mullins et al. "Fulminant Hypertension in Transgenic Rats Harboring the Mouse Ren-2 Gene", <i>Nature</i> , 344: 541-544, 1990.			
	264	Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucocytes", <i>Biochem. J.</i> , 192: 517-525, 1980.			
	265	Murray et al. "The Extracellular Matrix", <i>Harper's Biochemistry</i> , McGraw-Hill Professional, 24th Ed., Chap.57, P.667-685, 1998.			
	266	Nadav et al. "Activation, Processing and Trafficking of Extracellular Heparanase by Primary Human Fibroblasts", <i>Journal of Cell Science</i> , 115(10): 2179-2187, 2002.			
	267	Nakajima "Heparanases and Tumor Metastasis", <i>Tanpakushitsu Kakusan Koso</i> , 37(11): 1753-1758, 1992. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	21	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	268	Nakajima et al. "A Solid-Phase Substrate of Heparanase: Its Application to Assay of Human Melanoma for Heparan Sulfate Degradative Activity", Analytical Biochemistry, 157: 162-171, 1986.			
	269	Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metastatic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613, 1983.			
	270	Naparstek et al. "Activated T Lymphocytes Produce A Matrix-Degrading Heparan Sulphate Endoglycosidase", Nature, 310(5974): 241-244, 1984. Abstract.			
	271	Newbold et al. "Exposure to Diethylstilbestrol During Pregnancy Permanently Alters the Ovary and Oviduct", Biology of Reproduction, 28: 735-744, 1983. Abstract.			
	272	Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser, Boston, P.433, 492-495, 1994.			
	273	Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression in Septicemia and Septic Arthritis", Infect. Immun., 65(10): 4216-21, 1997. Abstract.			
	274	Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991. Abstract.			
	275	Novagen "PET System Manual", Novagen, 6th Ed., P.11, 1995.			
	276	Ofek et al. "Bacterial Adhesion to Cells and Tissues", Chapman & Hall, NY, P.114-118, 148-153, 418-423, 420-423, 1994.			
	277	Oldberg et al. "Characterization of A Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", Biochemistry, 19: 5755-5762, 1980.			
	278	Oosta et al. "Purification and Properties of Human Platelets Heparitanase", J. Biol. Chem., 257(19): 11249-11255, 1982.			
	279	Ornitz et al. "Heparin Is Required for Cell-Free Binding of Basic Fibroblast Growth Factor to A Soluble Receptor and for Mitogenesis in Whole Cells", Molecular and Cellular Biology, 12: 240-247, 1992.			
	280	Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa", FEMS Microbiol. Lett., 147(2): 195-202, 1997. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	22	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	281	Pearce et al. "Development of Glucose Intolerance in Male Transgenic Mice Overexpressing Human Glycogen Synthase Kinase-3? on A Muscle-Specific Promoter", Metabolism, 53(10): 1322-1330, 2004.			
	282	Pfaff et al. "Cryobiology of Rat Embryos I: Determination of Zygote Membrane Permeability Coefficients for Water and Cryoprotectants, Their Activation Energies, and the Development of Improved Cryopreservation Methods", Biology of Reproduction, 63: 1294-1302, 2000. Abstract.			
	283	Pier "Rationale for Development of Immunotherapies That Target Mucoïd Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst. Mitt., 98: 350-360, 1997. Abstract.			
	284	Pier et al. "Cystic Fibrosis Transmembrane Conductance Regulator Is An Epithelial Cell Receptor for Clearance of Pseudomonas Aeruginosa From the Lung", Proc. Natl. Acad. Sci. USA, 94(22): 12088-12093, 1997.			
	285	Pier et al. "How Mutant CFTR May Contribute to Pseudomonas Aeruginosa Infection in Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 154(4): S175-S182, 1996. Abstract.			
	286	Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human Parathyroid Hormone-Related Peptide (hPTHrP) of Malignancy on Bone Resorption and Formation in Organ Culture", Bone, 14: 717-720, 1993.			
	287	Pina et al. "The Role of Fluoroquinolones in the Promotion of Alginate Synthesis and Antibiotic Resistance in Pseudomonas Aeruginosa", Curr. Microbiol., 35(2): 103-108, 1997. Abstract.			
	288	Pomahac et al. "Tissue Engineering of Skin", Crit. Rev. Oral Biol. Med., 9(3): 333-344, 1998. Abstract.			
	289	Pralhada et al. "Diethylstilbestrol-Induced Cervical and Vaginal Adenosis Using the Neonatal Mouse Model", Biology of Reproduction, 38: 935-943, 1988. Abstract.			
	290	Prockop "Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues", Science, 276: 71-74, 1997.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/785,116
Filing Date	February 25, 2004
First Named Inventor	Iris PECKER et al
Art Unit	1652
Examiner Name	RICHARD G. HUTSON
Attorney Docket Number	27674

Sheet

23

Of

33

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	291	Quax et al. "Metastatic Behavior of Human Melanoma Cell Lines in Nude Mice Correlates With Urokinase-Type Plasminogen Activator, Its Type-1 Inhibitor, and Urokinase-Mediated Matrix Degradation", The Journal of Cell Biology, 115(1): 191-199, 1991.	
	292	Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci. USA, 95: 8910-8915, 1998.	
	293	Ragunath et al. "Cultured Epithelial Autografts: Diving From Surgery Into Matrix Biology", Pediatr. Surg. Int., 12(7): 478-483, 1997. Abstract.	
	294	Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991. Abstract.	
	295	Rajur et al. "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules", Bioconjugate Chem., 8: 935-940, 1997.	
	296	Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Environ. Microbiol., 67(1): 33-41, 2001. Abstract.	
	297	Ramsey et al. "Intermittent Administration of Inhaled Tobramycin in Patients With Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", New England Journal of Medicine, 340(1): 23-30, 1999. Abstract.	
	298	Reddi "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and Regeneration", Nature Biotechnology, 16: 247-252, 1998.	
	299	Richards et al. "Construction and Preliminary Characterization of the Rat Casein and Alpha-Lactalbumin cDNA Clones", J. Biol. Chem., 256(1): 526-32, 1981.	
	300	Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and Activity by Cell Density and Heparan Sulfate", J. Biological Chemistry, 274(19): 13534-13540, 1990.	
	301	Ricoveri et al. "Heparan Sulfate Endoglycosidase and Metastatic Potential in Murine Fibrosarcoma and Melanoma", Cancer Research, 46(8): 3855-3861, 1986. Abstract.	
Examiner Signature			Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	24	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	302	Robert et al. "Chondroitin-4-Sulphate (Proeoglycan), A Receptor for Plasmodium Falciparum-Infected Erthrocyte Adherence on Brain Microvascular Endothelial Cells", Res. Immunol., 146(6): 383-393, 1995. Abstract.			
	303	Rubin "Emerging Therapies for Cystic Fibrosis Lung Disease", Chest, 115: 1120-1126, 1999.			
	304	Sasisekharan et al. "Cloning and Expression of Heparinase I Gene From Flavobacterium Heparinum", Proc. Natl. Acad. Sci. USA, 90: 3660-3664, 1993.			
	305	Sasisekharan et al. "Heparinase Inhibits Neovascularization", Proc. Natl. Acad. Sci. USA, 91: 1524-1528, 1994.			
	306	Savion et al. "Murine Macrophage Heparanase: Inhibition and Comparison With Metastatic Tumor Cells", Journal of Cellular Physiology, 130: 77-84, 1987.			
	307	Schoepe et al. "Neutralization of Hemolytic and Mouse Lethal Activities of C. Perfringens Alpha-Toxin Need Simultaneous Blockage of Two Epitopes by Monoclonal Antibodies", Microb. Pathogenesis, 23(1): 1-10, 1997. Abstract.			
	308	Schultz et al. "Growth Factors in Preimplantation Mammalian Embryos", Oxford Review of Reproduction in Biology, 15: 43-81, 1993. Abstract.			
	309	Schwatz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower Respiratory Tract", J. Clin. Invest., 100(1): 68-73, 1997. Abstract.			
	310	Scott et al. "Visualization of An Extracellular Mucoid Layer of Treponema Denticola ATCC 35405 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral Microbiol. Immunol., 12(2): 121-125, 1997. Abstract.			
	311	Selvan et al. "Heparan Sulfate in Immune Responses", Ann. NY Acad. Sci., 797: 127-139, 1996.			
	312	Service "Tissue Engineers Build New Bone", Science, 289: 1498-1500, 2000.			
	313	Sewell et al. "Human Mononuclear Cells Contain An Endoglycosidase Specific for Heparan Sulfate Glycosaminoglycan Demonstrable With the Use of A Specific Solid-Phase Metabolically Radiolabelled Substrate", Biochem J., 264: 777-783, 1989.			
	314	Shakibaei et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate Proteoglycans", J. Exp. Med., 184(5): 1699-1711, 1996. Abstract.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	25	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	315	Shastri "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 181: 163-179, 1998.			
	316	Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14: 27-37, 1994/5.			
	317	Shimazu et al. "Syndecan-3 and the Control of Chondrocyte Proliferation During Endochondral Ossification", Exp. Cell. Res., 229(1): 126-136, 1996. Abstract.			
	318	Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era", Trends in Biotechnology, 18: 34-39, 2000.			
	319	Smith et al. "Expression of Heparan Sulfate Protoglycan (Perlecan) in the Mouse Blastocyst Is Regulated During Normal and Delayed Implantation", Dev. Biol., 184(1): 38-47, 1997. Abstract.			
	320	Smith et al. "The Challenges of Genome Sequence Annotation or 'The Devil Is in the Details'", Nature Biotechnology, 15: 1222-1223, 1997.			
	321	Sordat et al. "Modulation of the Malignant Phenotype With the Urokinase-Type Plasminogen Activator and the Type I Plasminogen Activator Inhibitor", Cell Differentiation and Development, 32: 277-286, 1990.			
	322	Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10", Cancer Res., 50: 6075-6086, 1990. Abstract.			
	323	Speert et al. "Modulation of Macrophage Function for Defense of the Lung Against Pseudomonas Aeruginosa", Behring Inst. Mitt., 98: 274-282, 1997. Abstract.			
	324	Spiegel et al. "Heparanase Facilitates Development and SDF-1 Induced Migration of Hematopoietic Stem and Progenitor Cells", Blood, 102(11): 825a-826a, 2003. Abstract# 3056.			
	325	Stracke et al. "Autotaxin, Tumor Motility-Stimulating Exophosphodiesterase", Advan. Enzyme Regul., 37: 135-144, 1997. Introduction.			
	326	Suggs et al. "Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human ?2-Microglobulin", Proc. Natl. Acad. Ssci. USA, 78(11): 6613-6617, 1981. P.6613.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	26	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	327	Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides", Biotech. Adv., 12: 393-448, 1994.			
	328	Szczylik et al. "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides", Science, 253: 562-565, 1991. Abstract.			
	329	Tang et al. "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to Pathogenesis of Pneumonia in A Neonatal Mouse Model of Infection", Infect. Immun., 64(1): 37-43, 1996. Abstract.			
	330	Tatnell et al. "Characterisation of Alginate From Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions, 24: 404S, 1996.			
	331	Tatnell et al. "Chemical Analysis of Alginates From Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions, 22: 310S, 1994.			
	332	Tatnell et al. "Colonisation of Cystic Fibrosis Patients by Non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate From Mucoid Variants", Biochemical Society Transactions, 24: 406S, 1996.			
	333	Taurog et al. "HLA-B27 in Inbred and Non-Inbred Transgenic Mice", The Journal of Immunology, 141(11): 4020-4023, 1988.			
	334	Taylor et al. "A Colorimetric Method for the Quantitation of Uronic Acids and A Specific Assay for Galacturonic Acid", Analytical Biochemistry, 201: 190-196, 1992.			
	335	Thompson et al. "Identification of Chondroitin Sulfate E in Human Lung Mast Cells", J. Immunol., 140(8): 2708-2713, 1988. Abstract.			
	336	Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical DNA by Oligonucleotides", Angew.Chem. Int. Ed. Engl. 32: 666-690, 1993.			
	337	Van Heeckeren et al. "Excessive Inflammatory Response of Cystic Fibrosis Mice to Bronchopulmonary Infection With Pseudomonas Aeruginosa", J. Clin. Invest., 100(11): 2810-2815, 1997.			
	338	Vernet et al. "Virulence Factors (Aerobactin and Mucoid Phenotype) in Klebsiella Pneumoniae and Escherichia Coli Blood Culture Isolates", FEMS Microbiol. Lett., 130(1): 51-57, 1995. Abstract.			
	339	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell, 19: 607-616, 1980.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	27	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	340	Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IMR-90) Maintained in A Low Concentration of Serum", Biochem. J., 207(3): 369-379. Abstract.			
	341	Vukicevic et al. "Induction of Nephrogenic Mesenchyme by Osteogenic Protein 1 (Bone Morphogenetic Protein 7)", Proc. Natl. Acad. Sci. USA, 93: 9021-9026, 1996.			
	342	Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neurotrophin Receptor With Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", Int. J. Cancer, 82: 112-120, 1999.			
	343	Wall "Transgenic Livestock: Progress and Prospects for the Future", Theriogenology, 45: 57-68, 1996.			
	344	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to A Structured RNA Target", Biotechnology and Bioengineering, 65(1): 1-9, 1999.			
	345	Wang "Basic Fibroblast Growth Factor for Stimulation of Bone Formation in Osteoinductive or Conductive Implants", Acta Orthop. Scand. Suppl., 269: 1-33, 1996. Abstract.			
	346	Wang "Basic Fibroblast Growth Factor Infused at Different Times During Bone Graft Incorporation. Titanium Chamber Study in Rats", Acta Orthop. Scand., 67(3): 229-236, 1996. Abstract.			
	347	Wang et al. "Basic Fibroblast Growth Factor Enhances Bone-Graft Incorporation: Dose and Time Dependence in Rats", J. Orthop. Res., 14(2): 316-323, 1996. Abstract.			
	348	Wang et al. "Isolation and Characterization of Pseudomonas Aeruginosa Genes Inducible by Respiratory Mucus Derived From Cystic Fibrosis Patients", Mol. Microbiol., 22(5): 1005-1012, 1996. Abstract.			
	349	Watson et al. "A Growth Factor Phenotype Map for Ovine Preimplantation Development", Biology of Reproduction, 50(4): 725-733, 1994. Abstract.			
	350	Webster et al. "FGFR Activation in Skeletal Disorders: Too Much of A Good Thing", TIG, 13(5): 178-182, 1997.			
	351	Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9): 698-702, 1975.			
Examiner Signature					Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	28	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	352	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target RNA Levels", Curr. Opin. Biotechnol., 9(5): 486-496, 1998. Abstract.			
	353	Weller "Implications of Early Inflammation and Infection in Cystic Fibrosis: A Review of New and Potential Interventions", Pediatric Pulmonology, 24: 143-146, 1997.			
	354	Wessels et al. "Effects on Virulence of Mutations in A Locus Essential for Hyaluronic Acid Capsule Expression in Group A Streptococci", Infect. Immun., 62(2): 433-441, 1994. Abstract.			
	355	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases", Journal of Biological Chemistry, 271(17): 10079-10086, 1996.			
	356	Wordinger et al. "The Immunolocalization of Basic Fibroblast Growth Factor in the Mouse Uterus During the Initial Stages of Embryo Implantation", Growth Factors, 11(3): 175-186, 1994. Abstract.			
	357	Yagel et al. "Normal Nonmetastatic Human Trophoblast Cells Share In Vitro Invasive Properties of Malignant Cells", J. Cellular Physiology, 136: 455-462, 1988.			
	358	Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Biochimica et Biophysica Acta, 1172: 37-42, 1993.			
	359	Ye et al. "Targeted Gene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, P.431-437, 1998.			
	360	Yesildaglar et al. "The Mouse as A Model to Study Adhesion Formation Following Endoscopic Surgery: A Preliminary Report", Human Reproduction, 14(1): 55-59, 1999. Abstract.			
	361	Yoshida "Effects of Basic Fibroblast Growth Factor on the Development of Mouse Preimplantation Embryos", Nippon Sanka Fujinka Gakkai Zasshi, 48(3): 170-176, 1996. Abstract.			
	362	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Pulmonary Clearance of Mucoic Pseudomonas Aeruginosa and Inflammation in A Mouse Model of Repeated Respiratory Challenge", Infection and Immunity, 66(1): 280-288, 1998.			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Application Number	10/785,116
Filing Date	February 25, 2004
First Named Inventor	Iris PECKER et al
Art Unit	1652
Examiner Name	RICHARD G. HUTSON
Attorney Docket Number	27674

Attorney Docket Number | 27674

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	30	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	371	Bar-Ner et al., "Inhibition of Heparanase-Mediated Degradation of Extracellular Matrix Heparan Sulphate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987.			
	372	Savitsky et al., "Ataxia-Telangiectasia: Structural Diversity of Untranslated Sequences Suggests Complex Post-Transcriptional Regulation of ATM Gene Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.			
	373	Haimovitz-Friedman et al., "Activation of Platelet Heparitinase by Tumor Cell-Derived Factors", Blood, 78(3): 789-796, 1991.			
	374	Gospodarowicz et al., "Stimulation of Corneal Endothelial Cell Proliferation In Vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 75-89, 1977.			
	375	Ernst et al., "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in Biochemistry and Molecular Biology, 30(5): 387-444, 1995.			
	376	Zhong-Sheng et al., "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J. Biol. Chem., 268(14): 10160-10167, 1993.			
	377	Ross, "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", Nature, 362: 801-809, 1993.			
	378	Putnak et al., "A Putative Cellular Receptor for Dengue Viruses", Nature Medicine, 3(8): 828-829, 1997.			
	379	Cordon-Cardo et al., "Expression of Basic Fibroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. Abstract.			
	380	Narindrasorasak et al., "High Affinity Interactions Between the Alzheimer's ?-Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", J. Biol. Chem., 266(20): 12878-12883, 1991.			
	381	Chen et al., "Dengue Virus Infectivity Depends on Envelope Protein Bin to Target Cell Heparan Sulfate", Nature Medicine, 3(8): 866-871, 1997.			
	382	Shieh et al., "Cell Surface Receptors for Herpes Simplex Virus Are Heparan Sulfate Proteoglycan Proteoglycans", J. Cell. Biol., 116(5): 1273-1281, 1992.			
	383	Eisenberg et al., "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan Sulfate on Cell Surface and Extracellular Matrix", Journal of Clinical Investigation, 90: 2013-2021, 1992.			
Examiner Signature					Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	31	Of	33	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	384	Rapraeger et al., "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252: 1705-1709, 1991.			
	385	Lider et al., "A Disaccharide That Inhibits Tumor Necrosis Factor ? Is Formed From the Extracellular Matrix by the Enzyme Heparanase", Proc. Natl. Acad. Sci. USA, 92: 5037-5041, 1995.			
	386	Lider et al., "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals With Low Doses of Heparin", The Journal of Clinical Investigation, 83: 752-756, 1989.			
	387	Gitay-Goren et al., "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules", Journal of Biological Chemistry, 267(9): 6093-6098, 1992.			
	388	Ornitz et al., "FGF Binding and FGF Receptor Activation by Synthetic Heparin-Derived Di- and Trisaccharides", Science, 268: 432-436, 1995.			
	389	Spivak-Kroizman et al., "Heparin-Induced Oligomerization of FGF Molecules Is Responsible For FGF Receptor Dimerization, Activation, and Cell Proliferation", Cell, 79: 1015-1024, 1994.			
	390	Yayon et al., "Cell Surface, Heparin-Like Molecules Are Required for Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor", Cell, 64: 841-848, 1991.			
	391	Vlodavsky et al., "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", in: Basic Membranes: Cellular and Molecular Aspects, Academic Press, Orlando, Fla., P. 327-343, 1993.			
	392	Vlodavsky et al., "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991.			
	393	Vlodavsky et al., "Involvement of the ExtraCellular Matrix, Heparin Sulfate Proteoglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and Metastis", Tumor Angeogenesis, P.125-140, 1997.			
	394	Vlodavsky et al., "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell, 19: 607-616, 1980.			
Examiner Signature					Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Complete if Known**

Application Number	10/785,116
Filing Date	February 25, 2004
First Named Inventor	Iris PECKER et al
Art Unit	1652
Examiner Name	RICHARD G. HUTSON

Sheet	32	Of	33	Attorney Docket Number	27674
-------	----	----	----	------------------------	-------

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	395	Vlodavsky et al., "Lymphoma Cell-Mediated Degradation of Sulfated Proteoglycans in the Subendothelial ExtraCellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Research, 43: 2704-2711, 1983.	
	396	Vlodavsky et al., "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species of Heparin", Invasion & Metastasis, 14(1-6): 290-302, 1994/95.	
	397	Vlodavsky et al., "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Isr. J. Med. Sci., 24(9-10): 464-470, 1988.	
	398	Vlodavsky et al., "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extra Vasion", Invasion & Metastasis, 12(2): 112-127, 1992.	
	399	Parish et al., "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor-Cell-Derived Heparanases", Int. J. Cancer, 40: 511-517, 1987.	
	400	Bashkin et al., "Basic Fibroblast Growth Factor Binds to Subendothelial ExtraCellular Matrix and Is Released by Heparitanase and Heparin-Like Molecules", Biochemistry, 28: 1737-1743, 1989.	
	401	Ishai-Michaeli et al., "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracellular Matrix", Cell Regulation, 1: 833-842, 1990.	
	402	Ishai-Michaeli et al., "Importance of Size and Sulfation of Heparin in Release of Basic Fibroblast Growth Factor From the Vascular Endothelium and ExtraCellular Matrix", Biochemistry, 31(7): 2080-2088, 1992.	
	403	Folkman et al., "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Factor - Is Stored Within Basement Membrane", Am. J. Pathology, 130(2): 393-400, 1988.	
	404	Folkman et al., "Angiogenic Factors", Science, 235: 442-447, 1987.	
	405	Gospodarowicz et al., "Permissive Effect of the ExtraCellular Matrix on Cell Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980.	
	406	Liotta et al., "Tumor Invasion and the ExtraCellular Matrix", Laboratory Investigation, 49(6): 636-647, 1983.	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	Iris PECKER et al
				Art Unit	1652
				Examiner Name	RICHARD G. HUTSON
Sheet	33	Of	33	Attorney Docket Number	27674

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.